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reported relapses (p  0.001 for both); there was no association between SF-12 and 
physician reported frequency of relapses. PCS-12 was also signiﬁcantly associated with 
physician-assessed severity of relapse (p  0.002 for typical; p  0.001 for worst 
relapse, respectively) as well as patient-assessed severity of relapse (p  0.001 for 
typical; p  0.001 for worst relapse). Mental scores, however, were not signiﬁcantly 
associated with physician- or patient-reported relapse severity. CONCLUSIONS: As 
a generic HRQoL tool, the SF-12 was associated with relapses in an MS population. 
In patient-reported, as opposed to neurologist-reported, frequency of relapses was 
associated with a lower HRQoL. Patient- and neurologist-assessed severity of relapses 
was linked to a lower physical QoL. These observations suggest that relapses, both in 
quantity and severity, have a negative impact on HRQoL as measured by the SF-12.
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OBJECTIVES: The aim of this study was to evaluate the impact of symptoms related 
to Parkinson’s disease (PD) on health-related quality of life. METHODS: Observa-
tional, multicenter, cross sectional study in patients with PD, older than 18, who had 
received PD medication for at least 1 year before inclusion. The following assessments 
were applied: Hoehn and Yahr staging of PD (HY), SCOPA-Motor (SC-M), Non-
Motor Symptoms Questionnaire (NMSQ), QUICK Questionnaire (QQ, for detection 
of wearing-off, WO) and PDQ-39 to evaluate quality of life in PD patients. RESULTS: 
1.173 evaluable patients were included, 58.6% were males, mean age (SD) was 71.4 
(8.6) years and most of them were in HY stage 2 or 3 (70.3%). According to SC-M, 
94.5% patients presented rigidity, 93.1% rapid alternating hand movements and 
84.5% alteration of walking. Mean score of SC-M and NMSQ was 19.3 (12.6) and 
9.7 (6.1) points, respectively. Regarding the quality of life evaluated using the PDQ-39 
questionnaire, global score was 26.6 (18.6) points. Spearman correlation coefﬁcients 
between PDQ-39 and the other measures were: HY, 0.55; SC-M, 0.76; NMSQ, 0.73; 
and QQ, 0.67. 59.2% patients presented WO according to QQ. Quality of life was 
better for patients without WO: PDQ-39 score 20.0 (17.4) vs 30.8 (18.2) points in 
patients with WO (p  0.0001). CONCLUSIONS: The results of this study suggest 
that Parkinson’s disease patients present a combination of motor and no-motor 
symptoms which affects quality of life. The presence of wearing off affects also the 
quality of life of these patients.
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OBJECTIVES: Benzodiazepines and Z-drugs are extensively prescribed in patients 
with insomnia, and their use raises public health concerns of dependence and increased 
indirect costs (e.g., falls). The aim of this study was to investigate prescribing practice 
patterns of Prolonged-Release Melatonin (PRM), a newly licensed hypnotic, in real-life 
settings using longitudinal prescription database analyses. METHODS: Longitudinal 
data of patients initiating PRM was extracted from a primary care prescription data-
base in Germany (IMS-DA). Patient characteristics (age, gender) and treatment infor-
mation (drug name, prescription date, number of packages and indication) were 
retrieved. Descriptive analyses investigated the proportion of patients with or without 
a past history of hypnotic use (deﬁned as at least one benzodiazepine or Z-drug (BZD-
Z) prescription within 3 months prior to PRM initiation). Descriptive statistics identi-
ﬁed the proportion of patients with or without BZD-Z prescriptions within the 3 
months following treatment initiation. Sensitivity analyses were performed on longer 
follow-up periods (6 months) and higher numbers of previous BZD-Z prescriptions 
(at least 2) to test the robustness of the ﬁndings. RESULTS: 1,382 eligible patient 
records were retrieved. Two-thirds were female (mean age 62). Among them, 512 
patients had a minimum 3-month history and 3-month follow-up. Approximately 
80% were not prescribed BZD-Z before PRM initiation and of those, 90% were still 
not prescribed any BZD-Z after 3 months. Among previous BZD-Z users, results 
showed that approximately 1/3 (36/112) were not prescribed any BZD-Z medication 
3 months after PRM initiation. Results were substantiated by sensitivity analyses on 
both longer follow-up duration and a greater number of previous BZD-Z prescrip-
tions. CONCLUSIONS: PRM might represent an interesting alternative to BZD-Z use 
for the treatment of insomnia. Further research with a larger study population is 
needed to conﬁrm these results.
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BACKGROUND: Chronic inﬂammatory demyelinating polyradiculoneuropathy 
(CIDP) is an acquired immune-mediated inﬂammatory disorder that targets the myelin 
sheaths of the peripheral nervous system. Intravenous immunoglobulin (IVIg) is a 
blood product containing immunoglobulin G (IgG) that has been pooled from many 
human donors. In the fall of 2008 CIDP became an approved indication for IVIg in 
both Canada and the United States. OBJECTIVES: To evaluate the clinical effective-
ness and safety of IVIg for the treatment of CIDP through a systematic review of the 
literature. METHODS: The Medline (1950–2009; In-Process & Other Non-Indexed 
Citations) and EMBASE (1980–2009) databases were searched through the Ovid 
interface. A methodological ﬁlter was applied to limit retrieval to clinical trials, MAs, 
or SRs. Retrieval was limited to humans and no language restrictions were employed. 
Extracted data were pooled to estimate the effect size of IVIg treatment based on the 
random-effects model. RESULTS: Nine unique RCTs were identiﬁed. Three of the 
nine trials compared IVIg therapy to an active comparator (plasma exchange (PE), PE 
using extracorporeal immunoadsorption, or oral prednisolone), and the other six trials 
were placebo-controlled. There was no incremental beneﬁt seen in the primary out-
comes when comparing IVIg therapy and the active comparator. Five of the six 
placebo-controlled trials showed IVIg therapy to be superior to placebo based upon 
a variety of disability or impairment outcomes. CONCLUSIONS: IVIg therapy is sta-
tistically superior to placebo treatment in reducing the disability and impairment for 
CIDP patients. IVIg demonstrates similar effectiveness as the alternative treatment 
strategies of PE and methyprednisolone.
PND47
ASSESSING CANADIANS’ WILLINGNESS-TO-PAY FOR ALZHEIMER’S 
DISEASE MEDICATIONS
Oremus M, Tarride JE, Raina P, Clayton N
McMaster University, Hamilton, ON, Canada
OBJECTIVES: In Canada, public drug plans provide limited reimbursement for 
Alzheimer’s disease (AD) medications. For most Canadians, the cost of these medica-
tions is paid ‘out-of-pocket’. This study was conducted to assess the Canadian general 
public’s willingness-to-pay (WTP) for unrestricted access to AD medications. 
METHODS: Five-hundred participants (age q18 years) were recruited nationally and 
stratiﬁed by income. Data were collected via computer-assisted telephone interviews. 
Participants were presented with four ‘efﬁcacy’ scenarios describing a hypothetical, 
new AD medication. In two scenarios, the medication was described as modifying the 
symptoms of cognitive decline. In the other two scenarios, the medication was 
described as halting disease progression. For each pair of ‘efﬁcacy’ scenarios, the 
medication was assumed to have no adverse effects in one scenario and a 30% chance 
of adverse effects in the other scenario. For every scenario, participants were asked 
whether they would support unrestricted access to the medication through an annual 
increase in personal income taxes. Participants then provided the maximum tax 
increase that they would support. WTP was elicited using a bid range: $75, $150, or 
$225. Open-ended questions allowed participants to specify values outside the range. 
Participants were randomized to order of scenarios and bids. Differences between 
scenarios were assessed using Bowker’s test of symmetry. RESULTS: Overall, 80% of 
participants (n  398) supported a tax increase under at least one scenario. Maximum 
WTP did not differ across scenarios (median  $150, interquartile range  $75 to $225 
[for all four scenarios]). After categorization ($75, $75, $150, $225,  $225), the 
distribution of maximum WTP did not differ by efﬁcacy (symptom modiﬁcation versus 
halting disease progression [p  0.34]) or adverse effects (30% chance versus none 
[p  0.54]). CONCLUSIONS: Most participants reported support for a tax increase. 
Once the decision was made to support an increase, maximum WTP was unaffected 
by efﬁcacy or the potential for adverse effects.
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OBJECTIVES: In Canada, the cost of Alzheimer’s disease (AD) medications is mainly 
borne by patients and caregivers. The primary objective of this study was to measure 
the Canadian general public’s support for a program of unrestricted access to AD 
medications. The secondary objective was to identify determinants of support for the 
program. METHODS: A national sample of 500 Canadians, aged 18 years or older, 
was randomly recruited to participate in a computer-assisted telephone interview. The 
sample was stratiﬁed by income. Participants were presented with a set of randomly-
ordered scenarios describing a hypothetical, new AD medication. The efﬁcacy of the 
medication was varied by scenario: the medication was alternately described as modi-
fying the symptoms of cognitive decline or actually halting disease progression. The 
adverse effects proﬁle was also varied in the scenarios: no adverse effects or a 30% 
chance of some adverse effects. For each scenario, participants were asked whether 
they supported an annual increase in personal income taxes to fund unrestricted access 
to the AD medication. Logistic regression was conducted to identify factors that might 
explain support for the tax increase. RESULTS: Percentage of respondents supporting 
a tax increase varied with scenario: symptom modiﬁcation and 30% chance of adverse 
effects  49% (n  244); symptom modiﬁcation, no adverse effects  58% (n  290); 
halt progression and 30% chance of adverse effects  54% (n  270); halt progression, 
no adverse effects  67% (n  333). Relative to the ‘symptom treatment and 30% 
chance of adverse effects’ scenario, the level of support was different (p  0.05) for 
all except the ‘halt progression and 30% chance of adverse effects’ scenario (p  0.15). 
No determinant (e.g., age, sex) could consistently explain support across all four 
 scenarios. CONCLUSIONS: Support for the tax increase varied by the efﬁcacy and 
